Glucocorticosteroids pregnancy

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

Glucocorticoids and pregnancy

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Inprinciple, the following points should be observed in systemic therapy with glucocorticoids during pregnancy (Schaefer C et al. 2012):

  • In general, non-halogenated systemic glucocorticoids should be used. These are largely inactivated in the placenta.
  • Prednisolone is the systemic glucocorticoid of choice (gradient mother: child = 10:1).
  • Prednisolone is generally considered safe during pregnancy (Ambros-Rudolph CM et al. 2017).
  • the usual dosage regimens can be maintained.
  • For the treatment of pregnancy dermatoses glucocorticoids are usually used as short-term therapy (< four weeks). No side effects are to be expected.
  • If a >10-day continuous glucocorticoid therapy is required in the 1st trimester, especially between weeks 8-11, the daily dose of 10-15 mg should not be exceeded! At higher doses a potential risk of cleft lip and palate cannot be excluded.
  • If high-dose treatment is required for many weeks until birth, fetal growth should be monitored sonographically and possible adrenal insufficiency of the newborn should be considered.

Topical therapy with glucocorticoid externa in pregnancy:

  • In the external application of glucocorticoids, preference should be given to newer, substituted, non-fluorinated preparations (e.g. prednicarbate, methylprednisolone aceponate, mometasone furoate) (note also inhaled glucocorticoids).
  • Highly effective topical glucocorticoids should not be used. They increase the risk of striae cutis distensae. The use of topical glucocorticoids has not been shown to increase the risk of malformation (especially cleft lip and palate), consultation, effects or premature birth.
  • The use of strong and very strong glucocorticoids and exceeding a cumulative total dose of 300 g was associated with reduced birth weight (Chi CC et al. 2013).

LiteratureThis section has been translated automatically.

  1. Ambros-Rudolph CM et al (2017): Specific dermatoses during pregnancy. Dermatologist 68: 87-94
  2. Chi CC et al (2013) Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study. JAMA Dermatol 149:1274-1280.
  3. Schaefer C et al (2012) Prescription in pregnancy and lactation, 8th ed. Urban & Fischer, Munich

Authors

Last updated on: 29.10.2020